Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Antonarakis, Emmanuel S.
Madison, Russell
Snider, Jeremy
Snow, Tamara
Sokol, Ethan
Chung, Jon
McCusker, Margaret Elizabeth
Singal, Gaurav
Alexander, Brian Michael
Castellanos, Emily
Venstrom, Jeffrey
Schrock, Alexa Betzig
Ross, Jeffrey S.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Flatiron Hlth, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5527
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Real-World Utilization And Outcomes Of Radium-223 In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
    Li, R.
    Dandapani, S. V.
    Amini, A.
    Pal, S. K.
    Dorff, T. B.
    Lyou, Y.
    Vapiwala, N.
    Wong, J. Y. C.
    Glaser, S. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E885 - E886
  • [32] Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    McNeel, Douglas G.
    Lin, Daniel W.
    Gardner, Thomas
    Sheikh, Nadeem A.
    Whitmore, James Boyd
    Sims, Robert Brownell
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Real-World experience with abiraterone in metastatic castrate-resistant prostate carcinoma in University Malaya Medical Centre
    Shariff, N.
    Shukor, S.
    Soosainathan, P.
    Subramaniam, S. K.
    Chan, M. J.
    Ong, T. A.
    Saad, M.
    Alip, A.
    BJU INTERNATIONAL, 2016, 118 : 33 - 33
  • [34] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
    Morris, Michael J.
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Armour, Alison A.
    Messmann, Richard Adam
    Groaning, Michael
    Robarts, Adam
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    Kuo, Phillip
    Kearney, Megan
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [36] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [38] PSA response and cabazitaxel outcomes stratified by prior docetaxel PSA response in metastatic castrate-resistant prostate cancer (mCRPC).
    Wee, Christopher Eing
    Nizam, Amanda
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Chen, Xiaoying
    Maroli, Kimberly
    Martin, Allison
    Bonham, Amanda
    Pietro, Carolyn
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 119 - 119
  • [39] Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).
    Batalini, Felipe
    Madison, Russell
    Pavlick, Dean C.
    Sokol, Ethan
    Snow, Tamara
    Sondhi, Arjun
    Frampton, Garrett M.
    Jenkins, Colby
    Garber, Judy Ellen
    Wulf, Gerburg M.
    Venstrom, Jeffrey Michael
    Tung, Nadine M.
    Castellanos, Emily
    Schrock, Alexa Betzig
    McGregor, Kimberly
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
    Gordoa, Teresa Alonso
    Goodman, Michael Moses
    Vulsteke, Christof
    Roubaud, Guilhem
    Zhang, Jingsong
    Parikh, Mamta
    Piulats, Josep M.
    Azaro, Analia
    James, Gareth D.
    Cavazzina, Riccardo
    Gangl, Eric
    Thompson, Jeff
    Pouliot, Gayle Pageau
    Kumar, Rakesh
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345